Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00

Xilio Therapeutics (NASDAQ:XLO) had its target price cut by Raymond James from $6.00 to $4.00 in a report issued on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Xilio Therapeutics Stock Performance

Shares of XLO opened at $0.99 on Friday. Xilio Therapeutics has a one year low of $0.49 and a one year high of $1.93. The stock has a market capitalization of $43.51 million, a price-to-earnings ratio of -0.58 and a beta of -0.24. The stock has a 50 day moving average price of $0.88 and a 200 day moving average price of $0.95.

Xilio Therapeutics (NASDAQ:XLO) last issued its earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $2.36 million during the quarter, compared to the consensus estimate of $30.00 million. On average, analysts predict that Xilio Therapeutics will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. XTX Topco Ltd acquired a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 33,289 shares of the company’s stock, valued at approximately $32,000. XTX Topco Ltd owned 0.08% of Xilio Therapeutics at the end of the most recent quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.